Search

Your search keyword '"Mauriac L"' showing total 538 results
Start Over Author "Mauriac L"
538 results on '"Mauriac L"'

101. Carcinomes canalaires in situ bilatéraux: événements indépendants ou maladie bilatérale?

Author

André, G., primary, Tunon-de-Lara, C., additional, Macgrogan, G., additional, Laharie-Mineur, H., additional, Bussieres, J.-E., additional, Valentin, F., additional, Barreau, B., additional, Dilhuydy, M.-H., additional, Dilhuydy, J.-M., additional, Mauriac, L., additional, Debled, M., additional, Durand, M., additional, Mathoulin, S., additional, and Avril, A., additional

Published
2007
Full Text
View/download PDF

104. BIG 1–98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

Author

Mouridsen, H. T., primary, Keshaviah, A., additional, Mauriac, L., additional, Forbes, J., additional, Paridaens, R., additional, Castiglione-Gertsch, M., additional, Gelber, R., additional, Smith, I., additional, Thuerlimann, B., additional, and Goldhirsch, A., additional

Published
2006
Full Text
View/download PDF

106. [Relay chemotherapy using continuous perfusion of cisplatin and fluoro-uracil in advanced cancer of the breast. Analysis of a series of 50 cases]

Author

Chauvergne J, Mauriac L, Durand M, David M, Alain Ravaud, and Bécouarn Y

Subjects
Antineoplastic Combined Chemotherapy Protocols, Drug Evaluation, Humans, Breast Neoplasms, Female, Fluorouracil, Cisplatin, Middle Aged, Infusions, Intravenous, Follow-Up Studies
Abstract

Fifty patients with advanced breast cancer (21 undergoing first and second stage palliative treatment: group 1, and 29 undergoing stage three or more: group 2), were included in a phase II trial with administration of a combination relay chemotherapy consisting of cisplatin (100 mg/m2/day) and fluorouracil (1,000 mg/m2/day), in continuous perfusion during 4 days, in cycles of five days repeated every three weeks (mean duration: 12 weeks). Toxicity was frequent and severe (a total of 17 treatments discontinued, and five deaths, 3 in group 1, 2 in group 2). The main manifestations of intolerance were threefold: haematological and leucopenia, in almost half of the patients, including 2 severe with 1 case of infectious complication and 4 thrombopenias requiring discontinuation of the treatment, including 2 with a severe haemorrhagic syndrome; cardiovascular, with three deaths due to heart failure; renal, most of the time laboratory tests disorders with 1 clinical syndrome. An objective response of more than fifty p. cent was obtained in five patients in group 1 (29.4%) and 3 patients in group 2 (11.1%); it lasted an average of 6.5 months and varied according to the locations: nodes (43%), liver (40%), pleuro-pulmonary (22%). Responses were obtained (13%) for lesions which resisted to previous chemotherapy. Five patients (14%) presented a functional improvement. The survival (mean = 4.8 months) was correlated, in group 1, to initial life conditions (p = 0.01) and was longer in group 1 for menopausal patients who had well tolerated the treatment (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1990

110. BIG 1–98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

Author

Thurlimann, B. J., primary, Keshaviah, A., additional, Mouridsen, H., additional, Mauriac, L., additional, Forbes, J. F., additional, Paridaens, R., additional, Castiglione-Gertsch, M., additional, Gelber, R. D., additional, Smith, I., additional, and Goldhirsch, A., additional

Published
2005
Full Text
View/download PDF

115. Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

Author

Mauriac, L, primary, Luporsi, E, additional, Cutuli, B, additional, Fourquet, A, additional, Garbay, J R, additional, Giard, S, additional, Spyratos, F, additional, Sigal-Zafrani, B, additional, Dilhuydy, J M, additional, Acharian, V, additional, Balu-Maestro, C, additional, Blanc-Vincent, M P, additional, Cohen-Solal, C, additional, De Lafontan, B, additional, Dilhuydy, M H, additional, Duquesne, B, additional, Gilles, R, additional, Lesur, A, additional, Shen, N, additional, Cany, L, additional, Dagousset, I, additional, Gaspard, M H, additional, Hoarau, H, additional, Hubert, A, additional, Monira, M H, additional, Perrié, N, additional, and Romieu, G, additional

Published
2003
Full Text
View/download PDF

116. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

Author

Piccart-Gebhart, Martine, Klijn, J G, Paridaens, R., Nooij, Marianne, Mauriac, L, Coleman, R, Bontenbal, M, Awada, Ahmad, Selleslags, Jean, Van Vreckem, Ann, van Glabbeke, Martine, Piccart-Gebhart, Martine, Klijn, J G, Paridaens, R., Nooij, Marianne, Mauriac, L, Coleman, R, Bontenbal, M, Awada, Ahmad, Selleslags, Jean, Van Vreckem, Ann, and van Glabbeke, Martine

Abstract

PURPOSE: To confirm the efficacy of docetaxel in patients with breast cancer previously treated with one chemotherapy regimen for advanced or metastatic disease and to compare the incidence of fluid retention (FR) and skin toxicity when docetaxel is administered with and without prophylactic corticosteroids. PATIENTS AND METHODS: Eighty-three patients, pretreated with one chemotherapy regimen for metastatic breast cancer (MBC) with bidimensionally measurable and progressive disease, were eligible for this randomized trial. Docetaxel with prophylactic oral antihistamine was administered at a dose of 50 mg/m2 as a 1-hour infusion on days 1 and 8 every 21 days and patients were randomized to receive methylprednisolone (40 mg days -1, 0, 1, 7, 8, and 9 of each cycle) (arm A) or no methylprednisolone (arm B). RESULTS: Twenty-eight patients (34%, 95% confidence interval [CI], 23% to 45%) achieved on objective response. The median time to disease progression and median overall survival time were 5 and 13.5 months, respectively. In total, 415 cycles of docetaxel were administered (arm A: N = 219, median = six; arm B: N = 196, median = five). The most common toxicity observed was grade 3 or 4 neutropenia, which occurred in 79% of patients. Clinically significant nonhematologic side effects included skin reactions and asthenia. In an intent-to-treat analysis, patients who received methylprednisolone premedication had a delayed onset of FR (median time to onset of FR: arm A, 84 days; arm B, 62 days; P = .01) and received a higher median cumulative dose of docetaxel before the onset of FR (arm A, 333 mg/m2; arm B, 215 mg/m2; P = .001). There was no statistically significant difference in the incidence of skin toxicity between the two arms. CONCLUSION: Docetaxel, at this dose and schedule, has definite antitumor activity in pretreated MBC patients. Moreover, this is the first randomized trial to show that corticosteroids have a favorable impact on docetaxel-induced FR., Clinical Trial, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, info:eu-repo/semantics/published

Published
1997

117. L’hormonothérapie néo-adjuvante en janvier 2005.

Author

Namer, Moïse, Héry, Michel, Serin, Daniel, Spielmann, Marc, Debled, M., Mauriac, L., MacGrogan, G., and Tunon de Lara, C.

Abstract

Copyright of Cancer du sein is the property of Springer Nature / Books and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2006
Full Text
View/download PDF

119. Analysis of 676 Cases of Ductal Carcinoma in Situ of the Breast From 1971 to 1995

Author

Tunon-de-Lara, C., primary, de-Mascarel, I., additional, Mac-Grogan, G., additional, Stöckle, E., additional, Jourdain, O., additional, Acharian, V., additional, Guegan, C., additional, Faucher, A., additional, Bussieres, E., additional, Trojani, M., additional, Bonichon, F., additional, Barreau, B., additional, Dilhuydy, M. H., additional, Dilhuydy, J. M., additional, Mauriac, L., additional, Durand, M., additional, and Avril, A., additional

Published
2001
Full Text
View/download PDF

120. ICI 182,780 (‘FASLODEX’) is at least as effective as anatrozole (Arimidex™) in post-menopausal women with advanced breast cancer progressing on prior endocrine treatment

Author

Howell, A., primary, Robertson, J.F.R., additional, Albano, J.Quaresma, additional, Aschermannova, A., additional, Mauriac, L., additional, Kleeberg, U.R., additional, Bergote, I., additional, Erikstein, B., additional, Webster, A., additional, and Morris, C., additional

Published
2001
Full Text
View/download PDF

124. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC)

Author

Leonard, R., primary, Cervantes, G., additional, Lui, W., additional, Mauriac, L., additional, Miles, D., additional, Moiseyenko, V., additional, Chan Navarro, C., additional, Van Hazel, G., additional, Vukelja, S., additional, and O'Shaughnessy, J., additional

Published
2001
Full Text
View/download PDF

127. Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients

Author

Bonneterre, J., primary, Spielman, M., additional, Guastalla, J.-P., additional, Marty, M., additional, Viens, P., additional, Chollet, P., additional, Roché, H., additional, Fumoleau, P., additional, Mauriac, L., additional, Bourgeois, H., additional, Namer, M., additional, Bergerat, J.P., additional, Misset, J.-L., additional, Trandafir, L., additional, and Mahjoubi, M., additional

Published
1999
Full Text
View/download PDF

128. The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study. Results of an EORTC — NCIC — SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)

Author

Therasse, P., primary, Mauriac, L., additional, Welnicka, M., additional, Bruning, P., additional, Cufer, T., additional, Lichinitser, R., additional, Pluzanska, A., additional, Tomiak, E., additional, Koopmanschap, M., additional, and Piccart, M., additional

Published
1999
Full Text
View/download PDF

141. Endometrial carcinoma (EC) in women with breast cancer (BC)

Author

Mignotle, H., primary, Lesur, A., additional, Luporsi, E., additional, Rodier, J.F., additional, Cutuli, B., additional, Lasry, S., additional, Mauriac, L., additional, Granon, C., additional, Kerr, C., additional, Giard, S., additional, Hill, C., additional, De Lafontan, B., additional, De Gislain, C., additional, D’Anjou, J., additional, Fondrinier, E., additional, Lefeuvre, C., additional, Lasset, C., additional, Bonadona, V., additional, and Chauvin, F., additional

Published
1997
Full Text
View/download PDF

146. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *

Author

Jonat, W., primary, Howell, A., additional, Blomqvist, C., additional, Eiermann, W., additional, Winblad, G., additional, Tyrrell, C., additional, Mauriac, L., additional, Roche, H., additional, Lundgren, S., additional, Hellmund, R., additional, and Azab, M., additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results